Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ProfoundBio Closes $70 Million Series A+ Funding for ADC and Immunotherapy Drugs

publication date: Jun 2, 2022

ProfoundBio, a Suzhou-Seattle ADC and immunotherapy company, closed a $70 million Series A+ financing round led by Sequoia China. Profound announced itself one year ago with $58 million in initial capital from China investors and a team that previously worked at SeaGen, a Seattle oncology company. The company is developing novel Antibody Drug Conjugates and T-Cell Engagers to address cancer. Profound will use the proceeds to advance its two lead ADC candidates into Phase I clinical trials. The company’s earlier investors -- Lilly Asia Venture, Oriza, Chang'an Capital, LYFE Capital, and K2VC – also participated in the A+ round. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China